Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00309
|
|||||
Drug Name |
Saquinavir
|
|||||
Synonyms |
(2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide; (2s)-N-[(2s,3r)-4-[(2s,3s,4as,8as)-3-(Tert-Butylcarbamoyl)-3,4,4a,5,6,7,8,8a-Octahydro-1h-Isoquinolin-2-Yl]-3-Hydroxy-1-Phenyl-Butan-2-Yl]-2-(Quinolin-2-Ylcarbonylamino)butanediamide; CIS-N-TERT-BUTYL-DECAHYDRO-2-[2(R)-HYDROXY-4-PHENYL-3(S)-[[N-2-QUINOLYLCARBONYL-L-ASPARAGINYL]AMINO]BUTYL]-(4AS)-ISOQUINOLINE-3(S)-CARBOXAMIDE; Fortovase; Fortovase (TN); Fortovase(TM); Invirase; Invirase (TN); Invirase(TM)(monomesylate); QNC-ASN-HPH-DIQ-NTB; ROC; Ro 31-8959; Ro 318959; Ro-31-8959; SQV; Saguinavir; Saquinavir (JAN/USP/INN)
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Human immunodeficiency virus infection [ICD11: 1C62.Z] | Approved | [1] | |||
Therapeutic Class |
Anti-HIV Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C38H50N6O5
|
|||||
Canonical SMILES |
CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O
|
|||||
InChI |
InChI=1S/C38H50N6O5/c1-38(2,3)43-37(49)32-20-26-14-7-8-15-27(26)22-44(32)23-33(45)30(19-24-11-5-4-6-12-24)41-36(48)31(21-34(39)46)42-35(47)29-18-17-25-13-9-10-16-28(25)40-29/h4-6,9-13,16-18,26-27,30-33,45H,7-8,14-15,19-23H2,1-3H3,(H2,39,46)(H,41,48)(H,42,47)(H,43,49)/t26-,27+,30-,31-,32-,33+/m0/s1
|
|||||
InChIKey |
QWAXKHKRTORLEM-UGJKXSETSA-N
|
|||||
CAS Number |
CAS 127779-20-8
|
|||||
Pharmaceutical Properties | Molecular Weight | 670.8 | Topological Polar Surface Area | 167 | ||
Heavy Atom Count | 49 | Rotatable Bond Count | 13 | |||
Hydrogen Bond Donor Count | 5 | Hydrogen Bond Acceptor Count | 7 | |||
XLogP |
4.2
|
|||||
PubChem CID | ||||||
PubChem SID |
10298771
, 103179606
, 104624996
, 104829254
, 11467142
, 11468262
, 11486850
, 117695825
, 14790389
, 14912870
, 24424137
, 24424140
, 24424146
, 24424150
, 26706895
, 36885127
, 46392170
, 46394116
, 46394117
, 47720800
, 47869868
, 48169598
, 48243608
, 49666064
, 49699303
, 49743129
, 49743137
, 49746604
, 50070617
, 50105601
, 53790242
, 56320473
, 57403600
, 596481
, 74519778
, 7847495
, 7890157
, 7890295
, 7980558
, 8030420
, 830611
, 838962
, 85177047
, 85788913
, 92715215
, 93166481
, 93167028
, 93617413
, 93617549
, 99453891
|
|||||
ChEBI ID |
CHEBI:63621
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
MRP1 | Transporter Info | Multidrug resistance-associated protein 1 | Substrate | [3] | ||
MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [4] | ||
OATP1A2 | Transporter Info | Organic anion transporting polypeptide 1A2 | Substrate | [5] | ||
OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [6] | ||
P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [7] | ||
Drug-Transporter Activity Data | ||||||
Drug-Transporter Activity Data | OATP1A2 | Transporter Info | Km = 36.4 microM | Oocytes-OATP1A2 | [5] | |
P-GP | Transporter Info | Km = 15.4 microM | Human enterocyte-like 2 cells (Caco-2)-MDR1 | [7] | ||
P-GP | Transporter Info | Km = 14.5 microM | LLC-PK1 cells-MDR1 | [8] | ||
References | ||||||
1 | Saquinavir was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Nicotine and cotinine increases the brain penetration of saquinavir in rat. J Neurochem. 2010 Dec;115(6):1495-507. | |||||
3 | Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother. 2002 Nov;46(11):3456-62. | |||||
4 | Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem. 2003 Jun 27;278(26):23538-44. | |||||
5 | Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56. | |||||
6 | Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. | |||||
7 | Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26. | |||||
8 | MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS. 2005 Oct 14;19(15):1617-25. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.